English 
Japanese 
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on 17th November, 2025. For more details, please click here (Japanese language PDF).
Category: News
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
PRISM BioLab Announces Achievement of Initial Milestone and Receipt of Upfront Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug discovery collaboration with Ono Pharmaceutical Co., Ltd. and will receive an upfront payment. For more details, please click here.
PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical
PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).
Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress
TOKYO, Japan, October 17, 2025: — PRISM BioLab announces that Eisai Co., Ltd. will present clinical trial results and biomarker exploration data for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 22, 2025....
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on September 30, 2025. For more details, please click here (Japanese language PDF).
Notice of Termination of Collaboration and Licensing Agreement with Servier
We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please click here (English language PDF).
Notice of Termination of Collaboration and Licensing Agreement with Eli Lilly and Company
We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please see the full announcement below: https://contents.xj-storage.jp/xcontents/AS09340/e4067309/8794/4b19/8225/2fb73b3fca54/140120250728521212.pdf
PRISM BioLab Announces Patent Acquisition for PepMetics® Technology Library Compounds
PRISM BioLab is pleased to announce that we obtained a patent for our novel compound library on May 30th, 2025. For more details, please click here (Japanese language PDF).
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
TOKYO, Japan, 23 May 2025: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd. , and Lenvatinib mesylate (“lenvatinib”) will be presented by...